Views: 0 Author: Site Editor Publish Time: 2026-06-18 Origin: Site
The 3-day CPHI China 2026 – the world’s leading pharmaceutical exhibition – came to a successful close at the Shanghai New International Expo Centre. Biocom made a strong impression at the event, showcasing its full-industry-chain core capabilities and accomplishing comprehensive brand exposure, business negotiations, industry benchmarking, and resource networking. During the exhibition, we received over 100 high-quality domestic and international customers and reached dozens of in-depth cooperation intentions, effectively strengthening our global pharmaceutical supply chain connectivity.
Leveraging our robust global compliance credentials, Biocom earned high recognition from visiting customers. All our R&D projects strictly adhere to ICH international guidelines. Our manufacturing subsidiary, Loncom Pharmaceuticals, has established a high-standard cGMP quality management system and holds both ISO 14001 (Environmental Management) and ISO 45001 (Occupational Health and Safety Management) certifications. With end-to-end integrated capabilities spanning API and FDF R&D, commercial production, global registration, and cross-border delivery, we are fully equipped to meet the standardized and customized pharmaceutical manufacturing needs of clients worldwide.
Backed by the tri-platform synergy of Shanghai Beike Biotechnology (innovative drug R&D), Loncom Pharmaceuticals (standardized manufacturing), and Biocom (MAH operation services), our team also gathered valuable frontline intelligence during the show. Through in-depth exchanges with industry peers, we captured emerging trends such as digital pharmaceuticals, low‑carbon synthesis, and evolving multi‑regional compliance requirements – providing key references for our future product iterations, service upgrades, and overseas market expansion.
This participation in CPHI Shanghai delivered multi‑faceted value: enhanced brand visibility on the global stage, expanded high‑quality client connections, cutting‑edge technology exchanges, and strengthened industrial synergies. The remarkable cooperation outcomes fully confirm the high recognition of Biocom’s product quality, compliance strength, and integrated service capabilities in the global pharmaceutical market. Guided by our core values of “Integrity, Innovation, Responsibility, and Sharing,” and backed by comprehensive global certifications, stable product supply, and integrated services, Biocom is committed to empowering global partners to reduce costs, improve efficiency, and achieve compliant growth.
Though the exhibition has ended, our collaboration continues. Looking ahead, Biocom will continue to deepen its presence in the high‑end API sector, accelerate investment in green low‑carbon manufacturing and AI‑driven R&D, further expand our global compliance portfolio, and steadily broaden our overseas footprint. We will actively collaborate with global industry partners to explore new opportunities, drive collaborative innovation, and contribute to the high‑quality, sustainable development of the global pharmaceutical industry.
